Travel in patients receiving TNF-alpha inhibitors

Robert Orenstein

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


The TNF-alpha inhibitors, infliximab (Remicade), etanercept (Enbrel) and adalimumab (Humira) are increasingly being used for chronic inflammatory diseases and have effectively allowed many patients to return to more active lifestyles. The impact of these agents on immune function has led to the recognition of specific infectious complications. The combination of the increasingly active lifestyles of those receiving these agents and their immunosuppressive effects pose new challenges for practitioners of travel medicine. The purpose of this article is to review the immunologic and infectious consequences of these therapies and their potential impact on travelers.

Original languageEnglish (US)
Pages (from-to)105-109
Number of pages5
JournalTravel Medicine and Infectious Disease
Issue number2
StatePublished - May 2005


  • Infectious complications
  • TNF inhibitors
  • Travel

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Travel in patients receiving TNF-alpha inhibitors'. Together they form a unique fingerprint.

Cite this